Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia Research Letter


Authors: Akiyama, H.; Nishida, Y.; Chang, K. H.; Bedoy, A. D.; Muftuoglu, M.; Ma, W.; Basyal, M.; Hirschi, Z.; Honma, D.; Tsutsumi, S.; Wang, J.; Zhang, W.; Huang, X.; Rampal, R. K.; Oluwole, O. O.; Bixby, D. L.; Daver, N. G.; Andreeff, M.
Title: Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia
Keywords: adult; cancer chemotherapy; cancer survival; controlled study; leukemia; cancer combination chemotherapy; nonhuman; cytarabine; letter; ki 67 antigen; cell proliferation; mouse; phenotype; cell cycle progression; apoptosis; animal experiment; animal model; in vitro study; tumor xenograft; protein p53; stem cell; flt3 ligand; oncogene c myc; azacitidine; cd33 antigen; leukemia remission; antileukemic activity; tumor microenvironment; transcription factor ezh2; oncogene n ras; acute myeloid leukemia; cell kinetics; refractory disease; cd123 antigen; human; rna sequencing; primary cell; venetoclax; ec50; adp ribosyl cyclase/cyclic adp ribose hydrolase 1; drug analysis; valemetostat
Journal Title: Blood Cancer Journal
Volume: 15
ISSN: 2044-5385
Publisher: Nature Publishing Group  
Date Published: 2025-04-24
Start Page: 76
Language: English
DOI: 10.1038/s41408-025-01266-0
PUBMED: 40274779
PROVIDER: scopus
PMCID: PMC12022017
DOI/URL:
Notes: Letter -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Raajit Kumar Rampal
    338 Rampal